Give the polio vaccine. For swine flu also they came here to vaccinate children but not adults” (urban SSI). A few noted unavailability of the vaccine during the pandemic as a reason: “There was no vaccine at that time when the illness more widespread. The vaccine came later” (46 yr, urban man, SSI). Nine respondents indicated that they wished to take the vaccine but were unable to do so as it was out of stock due to high demand. Seven respondents said they had no time to spare to go and get the vaccine. Financial constraints as a reason for not taking the vaccine were reported by 5 . Among these respondents, many stated that they would have taken it if the BLU-554 manufacturer government had provided the vaccine for free or at a discounted price. Insufficient indication of vaccine priority Some respondents explained that health care providers, the government or people they knew had not clearly indicated the importance of vaccination or encouraged it. An urban woman stated: “No one forced me or urged me to take the vaccine. No one asked me to come along to take it. Had someone urged me, I would have taken it. Neither the doctor nor family members urged me” (57 yr, SSI). The lack of a mandate by the government for pandemic influenza vaccination was also indicated as a reason by some: “The government did not carry out any promotional activities and there was no compulsion by the government to take the vaccine” (62 years, rural man, RM223). Other concerns Four respondents expressed concerns about vaccine effectiveness; 4 indicated a general avoidance of medication, and 1 mentioned a fear of adverse reactions. No one indicated otherHuman Vaccines ImmunotherapeuticsVolume 11 IssueTable 4. Preference for injectable or nasal pandemic influenza vaccine Overall Age group Area of residence SexYounger n D 436 More powerful vaccine ( )b Neither Both equal CV205-502 hydrochlorideMedChemExpress CV205-502 hydrochloride Injection Nasal spray Cannot say Safer vaccine ( )c Neither Both equal Injection Nasal spray Cannot say Personal preference ( )d No preference Injection Nasal sprayaOlder n D 213 0.0 3.3 44.1 28.6 23.9 0.9 7.5 59.6 25.4 6.6 14.6 57.8 27.p valueaUrban- Urban Rural Rural middle lowmore less income resource accessible accessible p valuea Female n D 102 0.0 2.9 42.2 33.3 21.6 0.0 9.8 46.1 42.2 2.0 n D 113 0.0 3.5 51.3 31.0 14.2 0.9 5.3 64.6 24.8 4.4 6.2 65.5 34.5 n D 113 0.0 1.8 40.7 37.2 20.4 0.0 14.2 54.9 25.7 5.3 10.6 54.9 28.3 n D 108 0.0 3.7 42.6 28.7 25.0 1.9 9.3 62.0 18.5 8.3 18.5 60.2 21.Malep valuean D 223 0.0 2.7 44.4 36.3 16.6 0.5 11.7 54.7 29.6 3.6 8.1 59.2 32.n D 221 n D 215 0.0 3.6 45.2 26.2 24.9 0.9 12.2 55.2 25.8 5.9 12.7 59.3 28.1 0.0 2.3 43.3 39.1 15.3 0.5 7.0 59.1 29.3 4.2 9.8 57.7 32.0.0 3.0 44.3 32.6 20.2 0.7 9.6 57.1 27.5 5.0 11.2 58.5 30.** ** ***9.8 52.9 37.*Fisher’s exact test was used to compare proportions across age groups, area of residence and sex, *p0.05, **p0.01, ***p0.001 Frequency of responses to the question: “Do you think either of these vaccines (the nasal spray or the injection) would be more powerful and better able to protect you against swine flu? . . . Why?” c Frequency of responses to the question: “Which one of these vaccines (nasal spray or injection) do you think would be safer for you? . . . Why?” d Frequency of responses to the question: “If you could choose either of these vaccines to protect yourself against swine flu, which one would you prefer, the nasal spray or the injection? . . . Why?” All questions were enquired in the local language, Marathi, and translations hav.Give the polio vaccine. For swine flu also they came here to vaccinate children but not adults” (urban SSI). A few noted unavailability of the vaccine during the pandemic as a reason: “There was no vaccine at that time when the illness more widespread. The vaccine came later” (46 yr, urban man, SSI). Nine respondents indicated that they wished to take the vaccine but were unable to do so as it was out of stock due to high demand. Seven respondents said they had no time to spare to go and get the vaccine. Financial constraints as a reason for not taking the vaccine were reported by 5 . Among these respondents, many stated that they would have taken it if the government had provided the vaccine for free or at a discounted price. Insufficient indication of vaccine priority Some respondents explained that health care providers, the government or people they knew had not clearly indicated the importance of vaccination or encouraged it. An urban woman stated: “No one forced me or urged me to take the vaccine. No one asked me to come along to take it. Had someone urged me, I would have taken it. Neither the doctor nor family members urged me” (57 yr, SSI). The lack of a mandate by the government for pandemic influenza vaccination was also indicated as a reason by some: “The government did not carry out any promotional activities and there was no compulsion by the government to take the vaccine” (62 years, rural man, RM223). Other concerns Four respondents expressed concerns about vaccine effectiveness; 4 indicated a general avoidance of medication, and 1 mentioned a fear of adverse reactions. No one indicated otherHuman Vaccines ImmunotherapeuticsVolume 11 IssueTable 4. Preference for injectable or nasal pandemic influenza vaccine Overall Age group Area of residence SexYounger n D 436 More powerful vaccine ( )b Neither Both equal Injection Nasal spray Cannot say Safer vaccine ( )c Neither Both equal Injection Nasal spray Cannot say Personal preference ( )d No preference Injection Nasal sprayaOlder n D 213 0.0 3.3 44.1 28.6 23.9 0.9 7.5 59.6 25.4 6.6 14.6 57.8 27.p valueaUrban- Urban Rural Rural middle lowmore less income resource accessible accessible p valuea Female n D 102 0.0 2.9 42.2 33.3 21.6 0.0 9.8 46.1 42.2 2.0 n D 113 0.0 3.5 51.3 31.0 14.2 0.9 5.3 64.6 24.8 4.4 6.2 65.5 34.5 n D 113 0.0 1.8 40.7 37.2 20.4 0.0 14.2 54.9 25.7 5.3 10.6 54.9 28.3 n D 108 0.0 3.7 42.6 28.7 25.0 1.9 9.3 62.0 18.5 8.3 18.5 60.2 21.Malep valuean D 223 0.0 2.7 44.4 36.3 16.6 0.5 11.7 54.7 29.6 3.6 8.1 59.2 32.n D 221 n D 215 0.0 3.6 45.2 26.2 24.9 0.9 12.2 55.2 25.8 5.9 12.7 59.3 28.1 0.0 2.3 43.3 39.1 15.3 0.5 7.0 59.1 29.3 4.2 9.8 57.7 32.0.0 3.0 44.3 32.6 20.2 0.7 9.6 57.1 27.5 5.0 11.2 58.5 30.** ** ***9.8 52.9 37.*Fisher’s exact test was used to compare proportions across age groups, area of residence and sex, *p0.05, **p0.01, ***p0.001 Frequency of responses to the question: “Do you think either of these vaccines (the nasal spray or the injection) would be more powerful and better able to protect you against swine flu? . . . Why?” c Frequency of responses to the question: “Which one of these vaccines (nasal spray or injection) do you think would be safer for you? . . . Why?” d Frequency of responses to the question: “If you could choose either of these vaccines to protect yourself against swine flu, which one would you prefer, the nasal spray or the injection? . . . Why?” All questions were enquired in the local language, Marathi, and translations hav.